Naveruclif (Paclitaxel)

Paclitaxel, the active ingredient in Naveruclif, is a Taxane presented as an intravenous solution for intravenous use. As a mitotic inhibitor, it is employed in the treatment of adult patients with solid tumours including breast, ovarian, non‑small cell lung, pancreatic cancers and Kaposi's sarcoma.

The product is manufactured in the European Union under strict GMP standards. GNH USA supplies Naveruclif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets.

Paclitaxel is a taxane chemotherapy agent used in the management of several solid tumours.

Breast cancer: administered as part of adjuvant or metastatic therapy to inhibit tumour growth and reduce disease burden. Ovarian cancer: used in combination regimens to improve response rates and prolong survival in advanced disease. Non‑small cell lung cancer: employed in first‑line or subsequent lines to extend patient survival. Pancreatic cancer: incorporated into combination protocols for metastatic disease to control tumour progression. Kaposi's sarcoma: applied in HIV‑negative patients to control lesion development and spread.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and fatigue: general malaise and reduced appetite.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including anaphylaxis and bronchospasm. - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess cardiac function: baseline ECG recommended due to potential arrhythmias. Evaluate liver function: dose adjustments may be needed in hepatic impairment. Avoid use in patients with known hypersensitivity to paclitaxel or its excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paclitaxel may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP2C8 inhibitors (e.g., gemfibrozil): may increase paclitaxel exposure. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Concurrent use with other myelosuppressive agents: heightened risk of severe neutropenia. - Concomitant anticoagulants: increased bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may modestly raise plasma levels. - Strong CYP2C8 inhibitors (e.g., clopidogrel): monitor for toxicity signs. - Neurotoxic agents (e.g., vincristine): may exacerbate peripheral neuropathy.